Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  signaling pathway targeted therapy, kinase inhibitor therapy, kinase targeted therapy
Trial Status:  Active
Results 1-25 of 1812 for your search:
Start Over
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-4438, B1771007, 2009-015498-11, NCT01180049
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RC08/29, NCT01320501
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001MIL04T, NCT01365468
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2011PTAHCC, NCT01409499
Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and ove
Sponsor: Other
Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UniHD-2010-11-40-1001, 2010-019748-38, NCT01553032
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV08, NCT01665417
An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GO28399, 2012-003144-80, NCT01739764
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: Not specifiec
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2X01B, NCT01789281
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TACE-Sorafenib, NCT01833299
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-213, NCT01849588
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XL184-401, NCT01896479
Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IV-49, NCT01926171
Influence of Exceptional Patient Characteristics on Everolimus Exposure
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO201301, NCT01948960
Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: MITOCET, 2013-001296-20, NCT02015650
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IMA_CML_IV, NCT02204722
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1200.217, 2014-001077-14, NCT02208843
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1871039, 2013-003250-25, NCT02228382
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: iOM-12293, NCT02248571
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: BPL-Nim-NPC-2, NCT02293356
Start Over